SCHEMBL1014092

SCHEMBL1014092

CON(C)C(=O)c1cccc(CN2CCOCC2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.50
KCNH2 Q12809 1/20 0.50
CA2 P00918 2/20 0.49
NCF1 P14598 1/20 0.49
NOS1 P29475 1/20 0.48
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
NPC1 O15118 2/20 0.47
TP53 P04637 2/20 0.47
RAB9A P51151 2/20 0.47
HIF1A Q16665 2/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
EPAS1 Q99814 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014491 0.85 HIF1A (0.61) KDM4EHPGDSMN1; SMN2LMNANPC1
SCHEMBL1013481 0.82 ALDH1A1 (0.62) ABL1KCNH2CA2NCF1NOS1
SCHEMBL30512200 0.82 ALDH1A1 (0.62) ABL1KCNH2CA2NCF1NOS1
SCHEMBL1014417 0.80 NOS1 (0.59) ABL1KCNH2CA2NCF1NOS1
SCHEMBL27789191 0.80 CA2 (0.68) ABL1KCNH2CA2NCF1NOS1
SCHEMBL1421404 0.80 CTSB (0.50) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL1014280 0.80 CYP2A13 (0.47) ALDH1A1KDM4EHTTSMN1; SMN2LMNA
SCHEMBL1011847 0.80 MCHR1 (0.48) KDM4EHPGDHTTSMN1; SMN2LMNA
SCHEMBL29865404 0.79 HIF1A (0.73) ABL1KCNH2CA2NCF1NOS1
SCHEMBL3829994 0.79 HIF1A (0.73) ABL1KCNH2CA2NCF1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-10 US disclosed
EP-2272835-A1 NOVEL FIVE-MEMBERED RING COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-01-12 EP disclosed
WO-2009131171-A1 NOVEL FIVE-MEMBERED RING COMPOUND 大日本住友製薬株式会社 (JP) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034466-A1 NOVEL FIVE-MEMBERED RING COMPOUND CCL11, CCR1, CCR10 ABL1 702/4885KCNH2 776/4885CA2 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.